Advertisement

European Archives of Oto-Rhino-Laryngology

, Volume 274, Issue 8, pp 3103–3107 | Cite as

Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital

  • Jingchao YanEmail author
  • Jianwen Shen
  • Ying Li
  • Fengmin Tang
  • Nianzu Chen
Rhinology

Abstract

We undertook this survey about the use of clarithromycin in the Ear, Nose, and Throat (ENT) Outpatient Department of Fudan University Hospital to understand its utilization patterns and rational use. A survey of prescriptions given to outpatients was carried out, and detailed information of the patients, including age, sex, diagnosis, combined medication, and other information, was recorded in Excel spreadsheets. The rationale for each prescription was evaluated retrospectively. Based on our analysis, 82.5% of the clarithromycin prescriptions were for the treatment of rhinosinusitis. It was found that the parameters for the diagnosis of this condition were surprisingly broad and should have been more specific. In addition, the clarithromycin dosage regimen varied in clinical practice. For chronic rhinosinusitis, the duration of treatment was between 8 and 16 days, which was not sufficient. Moreover, clarithromycin was prescribed along with considerable numbers of pharmacotherapeutic anti-allergic drugs. Our survey indicated that improvements in the quality of clarithromycin prescriptions in otolaryngology outpatients should be made. Furthermore, the importance of medical education to patients should be emphasized. In addition, the interaction between clarithromycin and other anti-allergic drugs requires further investigation.

Keywords

Clarithromycin Drug utilization Prescriptions Otolaryngology outpatients Drug interactions Antibiotics 

Notes

Compliance with ethical standards

Conflict of interest

We declare that we have no conflicts of interest.

Ethical approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The Ethics Committee of Shanghai Eye, Ear, Nose and Throat Hospital, Shanghai Fudan University, Shanghai, China, approved this study.

References

  1. 1.
    World Health Organization (WHO) (2011) Antimicrobial resistance and its global spread. http://www.who.int/world-health-day/en/index.html. Accessed 27 Sep 2016
  2. 2.
    Xiao Y, Zhang J, Zheng B et al (2013) Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med 10(11):1–4. doi: 10.1371/journal.pmed.1001556 CrossRefGoogle Scholar
  3. 3.
    Shimizu T, Suzaki H (2016) Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. Auris Nasus Larynx 43(2):131–136CrossRefPubMedGoogle Scholar
  4. 4.
    Fokkens W, Lund V, Mullol J et al (2007) EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 45(2):97–101PubMedGoogle Scholar
  5. 5.
    Shi Z-l, Peng H, Xian-Wei H et al (2014) Effectiveness and safety of macrolides in bronchiectasis patients: a meta-analysis and systematic review. Pulm Pharmacol Ther 28(2):171–178CrossRefPubMedGoogle Scholar
  6. 6.
    Korkmaz H, Ocal B, Tatar EC et al (2014) Biofilms in chronic rhinosinusitis with polyps: is eradication possible? Eur Arch Otorhinolaryngol 271(10):2695–2702CrossRefPubMedGoogle Scholar
  7. 7.
    Health Department of China (2007) Prescription administrative policy. http://www.gov.cn/flfg/2007-03/13/content_549406.htm. Accessed 22 Sep 2016
  8. 8.
    Harmes KM, Blackwood RA, Burrows HL et al (2013) Otitis media: diagnosis and treatment. Am Fam Phys 88(7):435–440Google Scholar
  9. 9.
    Vlastarakos PV, Manolopoulos L, Ferekidis E et al (2008) Treating common problems of the nose and throat in pregnancy: what is safe? Eur Arch Otorhinolaryngol 265(5):499–508CrossRefPubMedGoogle Scholar
  10. 10.
    Hare KM, Grimwood K, Chang AB et al (2015) Nasopharyngeal carriage and macrolide resistance in Indigenous children with bronchiectasis randomized to long-term azithromycin or placebo. Eur J Clin Microbiol Infect Dis 34(11):2275–2285CrossRefPubMedGoogle Scholar
  11. 11.
    Gao YP, Liu HQ, Liu HY et al (2012) Medication compliance analysis of adult chronic rhinosinusitis. J Clin Otorhinolaryngol Head Neck Surg (China) 26(05):224–225Google Scholar
  12. 12.
    Fan Y, Xu R, Hong H et al (2014) High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. J Laryngol Otol 128(03):236–241CrossRefPubMedGoogle Scholar
  13. 13.
    Niedrig D, Maechler S, Hoppe L et al (2016) Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol 72(7):859–867CrossRefPubMedGoogle Scholar
  14. 14.
    US Food & Drug Administration (2011) FDA Drug Development and Drug Interactions: Table of Substrates Inhibitors and Inducers. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#4. Accessed 27 Sep 2016
  15. 15.
    Carr RA, Edmonds A, Shi H et al (1998) Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration. Antimicrob Agents Chemother 42(5):1176–1180PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Jingchao Yan
    • 1
    Email author
  • Jianwen Shen
    • 1
  • Ying Li
    • 1
  • Fengmin Tang
    • 1
  • Nianzu Chen
    • 1
  1. 1.Department of PharmacyEye Ear Nose Throat Hospital of Fudan UniversityShanghaiChina

Personalised recommendations